Long-term CD4+ and CD8+ T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16)

Vaccine

Volumn 31, Issue 40, 2013, Pages 4406-4415

  Launay, Odile ^a   Surenaud, Mathieu ^b,k   Desaint, Corinne ^a   Ben Hamouda, Nadine ^b,l   Pialoux, Gilles ^c   Bonnet, Bénédicte ^d   Poizot Martin, Isabelle ^e   Gonzales, Gustavo ^f   Cuzin, Lise ^g   Bourgault Villada, Isabelle ^b,h   Lévy, Yves ⁱ   Choppin, Jeannine ^b   Durier, Christine ^j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT COCHIN   (France)

^c HÔPITAL TENON   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f Instilut Curie   (France)

^g CHU PURPAN   (France)

^h LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

ⁱ FACULTÉ DE MÉDECINE   (France)

^j INSERM   (France)

^k UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

HIV 1 vaccine; Intradermal injection; Lipopeptides; Randomised trial

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOPEPTIDE 4 VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VACCINATION;

HIV-1 VACCINE; INTRADERMAL INJECTION; LIPOPEPTIDES; RANDOMISED TRIAL;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEALTHY VOLUNTEERS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; LIPOPEPTIDES; PROSPECTIVE STUDIES; VACCINATION;

EID: 84882823975     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.102     Document Type: Article

References (63)

1. Klinguer C., David D., Kouach M., Wieruszeski J.M., Tartar A., Marzin D., et al. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate. Vaccine 1999, 18(3-4):259-267.
2. Gahéry-Ségard H., Pialoux G., Charmeteau B., Sermet S., Poncelet H., Raux M., et al. T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000, 74(4):1694-1703.
3. Pialoux G., Gahéry-Ségard H., Sermet S., Poncelet H., Fournier S., Gérard L., et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001, 15(10):1239-1249.
4. +-T-cell epitopes recognized. J Virol 2003, 77(20):11220-11231.
5. Lévy Y., Gahéry-Ségard H., Durier C., Lascaux A.S., Goujard C., Meiffrédy V., et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005, 19(3):279-286.
6. Lévy Y., Durier C., Lascaux A.S., Meiffrédy V., Gahéry-Ségard H., Goujard C., et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006, 20(3):405-413.
7. Gahery H., Daniel N., Charmeteau B., Ourth L., Jackson A., Andrieu M., et al. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses 2006, 22(7):684-694.
8. Pialoux G., Quercia R.P., Gahery H., Daniel N., Slama L., Girard P.M., et al. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin Vaccine Immunol 2008, 15(3):562-568.
9. Hunter J.A.A., Savin J.A., Dahl M.V. Clinical dermatology 1995, Blackwell Science, Oxford.
10. Bonini C., Lee S.P., Riddell S.R., Greenberg P.D. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 2001, 166(8):5250-5257.
11. Andrieu M., Loing E., Desoutter J.F., Connan F., Choppin J., Gras-Masse H., et al. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur J Immunol 2000, 30(11):3256-3265.
12. Andrieu M., Desoutter J.F., Loing E., Gaston J., Hanau D., Guillet J.G., et al. Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 2003, 77(2):1564-1570.
13. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., Bancroft W.H. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985, 254(22):3203-3206.
14. Bryan J.P., Sjogren M.H., Perine P.L., Legters L.J. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992, 14(3):697-707.
15. Briggs D.J., Banzhoff A., Nicolay U., Sirikwin S., Dumavibhat B., Tongswas S., et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000, 78(5):693-698.
16. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351(22):2286-2294.
17. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(22):2295-2301.
18. Van Rooij E.M., Haagmans B.L., de Visser Y.E., de Bruin M.G., Boersma W., Bianchi A.T. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs. Vet Immunol Immunopathol 1998, 66(2):113-126.
19. Förg P., von Hoegen P., Dalemans W., Schirrmacher V. Superiority of the ear pinna over muscle tissue as site for DNA vaccination. Gene Ther 1998, 5(6):789-797.
20. Ito K., Ito K., Shinohara N., Kato S. DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response. Mol Immunol 2003, 39(14):847-854.
21. Lodmell D.L., Parnell M.J., Weyhrich J.T., Ewalt L.C. Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody. Vaccine 2003, 21(25-26):3998-4002.
22. Méndez S., Belkaid Y., Seder R.A., Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 2002, 20(31-32):3702-3708.
23. Launay O., Durier C., Desaint C., Silbermann B., Jackson A., Pialoux G., et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS ONE 2007, 2(8):e725.
24. BenMohamed L., Krishnan R., Longmate J., Auge C., Low L., Primus J., et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 2000, 61(August (8)):764-779.
25. Dausset J., Pla M. HLA: complexe majeur d'histocompatibilité de l'homme 1989, Flammarion, Paris, p. 588.
26. Histocompatibility testing 1984 1984, Springer-Verlag, Heidelberg. E.D. Albert, M.P. Baur, W.R. Mayr (Eds.).
27. Deprez B., Sauzet J.P., Boutillon C., Martinon F., Tartar A., Sergheraert C., et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 1996, 14(April (5)):375-382.
28. Zhu X., Ramos T.V., Gras-Masse H., Kaplan B.E., BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol 2004, 34(November (11)):3102-3114.
29. Martinon F., Gras-Masse H., Boutillon C., Chirat F., Deprez B., Guillet J.G., et al. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol 1992, 149(November (10)):3416-3422.
30. Sauzet J.P., Déprez B., Martinon F., Guillet J.G., Gras-Masse H., Gomard E. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine 1995, 13(October (14)):1339-1345.
31. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995, 95(January (1)):341-349.
32. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989, 19(December (12)):2237-2242.
33. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(March (6673)):245-252.
34. Pimorady-Esfahani A., Grounds M.D., McMenamin P.G. Macrophages and dendritic cells in normal and regenerating murine skeletal muscle. Muscle Nerve 1997, 20(February (2)):158-166.
35. Wiendl H., Hohlfeld R., Kieseier B.C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005, 26(July (7)):373-380.
36. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4(March (3)):211-222.
37. Valladeau J., Saeland S. Cutaneous dendritic cells. Semin Immunol 2005, 17(August (4)):273-283.
38. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29(September (3)):497-510.
39. Launay O., van der Vliet D., Rosenberg A.R., Michel M.L., Piroth L., Rey D. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011, 305(14):1432-1440.
40. Sangaré L., Manhart L., Zehrung D., Wang C.C. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009, 27(12):1777-1786.
41. Bakari M., Aboud S., Nilsson C., Francis J., Buma D., Moshiro C., et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011, 29(46):8417-8428.
42. Meyer J., Harris S.A., Satti I., Poulton I.D., Poyntz H.C., Tanner R., et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine 2013, 31(February (7)):1026-1033.
43. Bansal A., Jackson B., West K., Wang S., Lu S., Kennedy J.S., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008, 82(13):6458-6469.
44. Rahman F., Dahmen A., Herzog-Hauff S., Böcher W.O., Galle P.R., Löhr H.F. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000, 31(2):521-527.
45. Vogt A., Mahé B., Costagliola D., Bonduelle O., Hadam S., Schaefer G., et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol 2008, 180(3):1482-1489.
46. Keating S.M., Bejon P., Berthoud T., Vuola J.M., Todryk S., Webster D.P., et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005, 175(9):5675-5680.
47. Winstone N., Guimarães-Walker A., Roberts J., Brown D., Loach V., Goonetilleke N., et al. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol 2009, 39(4):975-985.
48. Liard C., Munier S., Arias M., Joulin-Giet A., Bonduelle O., Duffy D., et al. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine. 2011, 29(August (37)):6379-6391.
49. Liard C., Munier S., Joulin-Giet A., Bonduelle O., Hadam S., Duffy D., et al. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol 2012, 132(March (3 Pt 1)):615-625.
50. ®)-Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine 2012, 30(June (27)):4046-4054.
51. Altfeld M., Kalife E.T., Qi Y., Streeck H., Lichterfeld M., Johnston M.N., et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med 2006, 3(10):e403.
52. Ferrari G., Neal W., Ottinger J., Jones A.M., Edwards B.H., Goepfert P., et al. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. J Immunol 2004, 173(3):2126.
53. Co M.D., Kilpatrick E.D., Rothman A.L. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology 2009, 128(September (1 Suppl.)):e718-e727.
54. Milich D.R., McLachlan A., Thornton G.B., Hughes J.L. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 1987, 329(October (6139)):547-549.
55. Bartholdy C., Stryhn A., Christensen J.P., Thomsen A.R. Single-epitope DNA vaccination prevents exhaustion and facilitates a broad antiviral CD8+ T cell response during chronic viral infection. J Immunol 2004, 173(November (10)):6284-6293.
56. Gowans E.J., Roberts S., Jones K., Dinatale I., Latour P.A., Chua B., et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010, 53(October (4)):599-607.
57. Karwacz K., Bricogne C., MacDonald D., Arce F., Bennett C.L., Collins M., et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med. 2011, 3(October (10)):581-592.
58. Frimpong-Boateng K., van Rooijen N., Geiben-Lynn R. Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta. PLoS ONE 2010, 5(August (8)):e12281.
59. Saitoh A., Narita M., Watanabe N., Tochiki N., Yamahira A., Nakamura T., et al. WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Med Oncol 2011, 28(March (1)):219-230.
60. Salmon-Céron D., Durier C., Desaint C., Cuzin L., Surenaud M., Hamouda N.B., et al. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 2010, 24(14):2211-2223.
61. Cobb A., Roberts L.K., Palucka A.K., Mead H., Montes M., Ranganathan R., et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods 2011, 365(1-2):27-37.
62. Levy Y., Thiébaut R., Montes M., Lacabaratz C., Sloan L., King B., et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T cell immunity associated with control of viral load 2013, in press.
63. Richert L., Hue S., Hocini H., Raimbault M., Lacabaratz C., Surenaud M Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS 2013, 27(9):1421-1431.